Pharmaceutical CEO Lowers Daraprim Price After Public Protest

After public protest to a 5000% price hike by Turing Pharmaceuticals that caused the drug Daraprim to increase from $13.50 to $750, the CEO Martin Shkreli has decided that he will lower the price, according to NBC News.

According to The New York Times, the drug Daraprim is typically used for those suffering from toxoplasmosis and those with weak immune systems, such as patients with cancer and AIDS. With the high cost of healthcare, the public became very critical of Shkreli's decision and he received backlash.

NBC News reported that the price hike was a result of Turing Pharmaceuticals not succeeding financially from the drug. However, many criticized his decision, including Hillary Clinton who tweeted "Price gouging like this in the specialty drug market is outrageous." 

While Shkreli did not specify what the new price would be, he assured that it would change over the next couple of weeks. 

More From LATF USA

Scroll to Top